Video

Dr. Ruan Discusses Biomarkers in MCL

Author(s):

Jia Ruan, MD, PhD

In Partnership With:

Jia Ruan, MD, PhD, associate professor of clinical medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses biomarkers in mantle cell lymphoma.

Jia Ruan, MD, PhD, associate professor of clinical medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses biomarkers in mantle cell lymphoma (MCL).

One of the challenges that persists in the treatment of patients with MCL is selection for therapies. Ruan says biomarkers need to be identified to predict risk or responsiveness to agents or combinations of agents. This would require an additional and concerted effort, Ruan says, and would be best investigated in a prospective clinical trial.

Ruan suggests that collecting clinical, pathological, and biomarker data in a prospective clinical trial could subsequently lead to more specific treatment regimens for patients with MCL.

Related Videos
Jennifer Scalici, MD
Steven H. Lin, MD, PhD
Anna Weiss, MD, associate professor, Department of Surgery, Oncology, associate professor, Cancer Center, University of Rochester Medicine
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Victor Moreno, MD, PhD
Tiago Biachi, MD, PhD
Dr Girard on De Novo and Acquired Resistance Alterations in HER2-Altered NSCLC
Elias Jabbour, MD
Daniel DeAngelo, MD, PhD
Douglas W. Sborov, MD, MS
Related Content
Michael Wang, MD
November 5th 2024

Indirect Comparison Shows Comparable Efficacy, Improved Safety for Acalabrutinib vs Ibrutinib in R/R Mantle Cell Lymphomal Lymphoma

Matthew Lunning, DO, FACP, associate professor, Division of Oncology & Hematology, associate vice chair, research, Department of Internal Medicine, assistant vice chancellor, clinical research, University of Nebraska Medical Center; Sarah Rutherford, MD, assistant professor, medicine, Division of Hematology/Oncology, Weill Cornell Medicine
April 18th 2024

Lunning and Rutherford Detail Considerations for BV-AVD Use in Older Patients With Hodgkin Lymphoma

Michael Wang, MD
October 22nd 2024

Acalabrutinib Plus Venetoclax/Rituximab Yields 100% ORR in Treatment-Naive Mantle Cell Lymphoma

Lori A. Leslie, MD
February 27th 2023

FDA Approval Insights: Pirtobrutinib in MCL

Perioperative nivolumab receives FDA approval for resectable NSCLC, acalabrutinib sNDA gets priority review for MCL, and more from OncLive this week.
October 5th 2024

The OncFive: Top Oncology Articles for the Week of 9/29

FDA recap thumb
October 4th 2024

OncLive’s September Roundup of Key FDA Approvals in Oncology